Incubator-CRO/CMO Alliances: Quicker, Cheaper & More Efficient

Wednesday, November 6 2013
4:00 pm – 7:00 pm

Location: Biotech 4 at 377 Plantation St, Mass Biotech Research Park, Worcester, MA

The shared space model in conjunction with utilizing external resources provided by local CRO/CMOs provides more efficient options for emerging companies. Startup biotech companies turn to incubation to conserve capital and extend their capabilities through access to shared resources.  

“Virtual Companies vs Bricks and Mortar” is an artificial contrast.  Most biotech companies, especially startups, are a hybrid model, with deep expertise in a limited area and the need to outsource the rest. 

The new wave of outsourcing is becoming as vital to big pharma as it is to startups.  Quality, turnaround speed, cost and trust-based relationships are the most important criteria in choosing CRO/CMO partners, and there can be many. The “Distributed Research Model,” using different providers for different services, is based solely on who can do what you need the best. Now CROs are becoming incubators to make more efficient use of their resources as well. 

Our panelists will provide incubator, CRO/CMO and entrepreneur perspectives on how to:

  •  Build a solid  CMO/CRO service business model
  • Select the right real estate/incubator space that meets your scientific and financial requirements/needs
  • Create the collaborations and partnerships you need for long term success.


  • 4-4:30 Registration, networking & optional tour
  • 4:45 Introduction from Michael F. Collins, MD, FACP, University of Massachusetts Medical School Chancellor
  • Moderated panel discussion with audience Q&A
  • 6-7pm Reception, networking, optional tour


  • Marc Bazin, CEO, HepatoChem
  • Martha C. Farmer, PhD President &  CEO, North Shore InnoVentures
  • Jeffrey P. Kiplinger PhD, Founder, President & CEO of Averica Discovery Services
  • Ania Knap, Partner & Co-Founder, New England PharmAssociates, LLC
  • Kevin O’Sullivan, President & CEO, Massachusetts Biomedical Initiatives
  • Raj Rajur, PhD, Chairman & CEO, CreaGen Biosciences, Inc.


  • Peter Abair, Director of Economic  & Global Affairs, MassBio



Click here for directions.

Click here for UMass Medical site plan.


This Forum is presented by the CRO/CMO Forum Working Group and is free and open to all.


Speaker Bios:


Peter Abair, Director of Economic  & Global Affairs, MassBio

Peter Abair is MassBio’s Director of Economic  and Global Affairs. In his position, he provides consulting services to companies looking to locate to or grow in Massachusetts, manages MassBio's global partners programs, and leads the development and publication of the Industry Snapshot - MassBio's annual economic analysis of the life sciences industry.  Prior to joining MassBio, he served the Commonwealth of Massachusetts in several economic development functions including Director of the Massachusetts Department of Economic Development, Massachusetts Office of Business Development, and Associate Director of the Massachusetts Department of Housing and Community Development. He has served in the administrations of four governors and began his career on the Washington, D.C. staff of the late Congressman Silvio O. Conte.  Peter holds a Bachelor of Arts degree in History and International Relations from Boston University and a Masters in Public Policy and Administration from the University of Massachusetts at Amherst. 

Michael F. Collins, MD, FACP, University of Massachusetts Medical School Chancellor

Dr. Collins, was appointed Chancellor of the University of Massachusetts Medical School by the Board of Trustees on September 26, 2008. From June 2007 to September 2008, Dr. Collins served as the medical school’s interim chancellor. Also in June 2007, Dr. Collins was appointed Senior Vice President for Health Sciences at the University of Massachusetts. Dr. Collins currently oversees the University of Massachusetts system-wide health and life sciences portfolio, charged with leading strategic initiatives to strengthen the university’s efforts in the area and to engage more fully with the Commonwealth’s dynamic health and life sciences sector.

As Chancellor of the University of Massachusetts Medical School, Dr. Collins provides critical direction and leadership to the campus' continuing efforts to distinguish itself as a premier academic health sciences center of national and international distinction. Dr. Collins directs the campus' institutional advancement, fundraising and external outreach efforts, focusing on expanding and enhancing relationships with the University of Massachusetts and its Board of Trustees; the UMass Memorial Health Care System; the communities served by the medical school; state and federal governmental entities; foundations, corporations and the philanthropic community; and international partners. In addition, he provides strategic management to a burgeoning UMass Medical School enterprise, which generates more than $900 million in annual revenues and includes: the School of Medicine, the Graduate School of Biomedical Sciences and the Graduate School of Nursing; more than 1,100 graduate-level students and a workforce of 6,800; a number of complex and diversified business units such as Commonwealth Medicine and MassBiologics of UMMS; and a thriving $250 million research portfolio.

Martha C. Farmer, PhD, President and CEO, North Shore InnoVentures

Martha C. Farmer, PhD is President, CEO and Founder, North Shore InnoVentures, a non-profit business incubator for life sciences and cleantech start-ups in Beverly, MA.  Prior to founding NSIV Martha had a consulting practice in medical ethics and drug development. She serves on the Institutional Review Board and the Ethics Committee of Northeast Hospital Systems.  She also serves on the Board of Trustees of the North Shore Community College and on the Board of Directors of the North Shore Technology Council and the Life Sciences Consortium of the North Shore.  Formerly with Baxter Healthcare’s Hemoglobin Therapeutics Division, she transitioned from managing the research laboratory to directing product development, communications and business development. Subsequently she consulted in clinical trial planning and analysis for two small public companies in the hemoglobin therapeutics field, Hemosol and Biopure.  She co-founded the radiopharmaceutical start-up, BetaGamma LLC, serving as Vice President of Marketing. She also served as bioethics adviser to StemCore, a stem cell research review startup.  She obtained a BS in zoology and a PhD in physiology and pharmacology from Duke University, postdoctoral training in biophysics from Johns Hopkins University and was a fellow in Medical Ethics at Harvard University.  She is an author on more than 30 publications and three patents.

Jeffrey P. Kiplinger PhD, founder, President & CEO of Averica Discovery Services

Dr. Kiplinger has 25 years of experience in the pharmaceutical industry, initially as a mass spectrometrist and analytical chemist and later as a strategic consultant to startup companies.  Presently he is the founder, President and CEO of Averica Discovery Services, an analytics Contract Research Organization in Worcester, Massachusetts.

Dr. Kiplinger received his PhD at Indiana University in 1984.  He joined Pfizer’s Drug Discovery research center in Groton, Connecticut, where he led the automation of drug discovery that took place in the 1990s. After leaving Pfizer, Dr. Kiplinger founded the Gilson Center for Integrated Discovery Technology (CIDT) in Rhode Island and began a successful consulting firm.  He developed business plans for the Piedmont Triad Research Park and Rhode Island’s Slater Center incubator.  In 2007, he was asked to create a contract research company to better meet the needs of several clients, and founded Averica.

Dr. Kiplinger has published over 30 research papers, in addition to recent articles on high-throughput technologies and laboratory form and function.  He is a frequent invited speaker at conferences and meetings.  He has a strong interest in scientific entrepreneurship.

Ania Knap, Partner & Co-Founder, New England PharmAssociates, LLC

Ania is a life-sciences entrepreneur and consultant with more than 20 years experience in pharmaceutical research, early development and business strategy and development. She is a Partner and co-founder of New England PharmAssociates, LLC, a research services provider and consultancy based in Reading, MA. She is an Entrepreneur-in-Residence, Advisor and Leadership Team at North Shore InnoVentures in Beverly, MA.

In 2004, she co-founded MaxThera, Inc, a pharmaceutical research company developing novelantibacterial agents to treat life-threatening infections caused by antibiotic resistant pathogens. She served as President and Chief Scientific Officer of the company. MaxThera was formed through acquisition of the drug discovery portfolio Ania had developed as head of discovery research at Genome Therapeutics. The company was funded initially by the US BioShield Program and SBIR grants administered through the NIAID (NIH). MaxThera’s antibacterial assets were sold in 2010 to Biota Holdings Limited, a Melbourne Australia anti-infectives company.

Prior to starting MaxThera, Ania was Sr. Director of Discovery Research at Genome Therapeutics, a role she took on following a her role as Head of Enzymology at Kinetix, In Cambridge, MA, where her expertise in kinase enzymology played a key role in preparing the company for its acquisition by Amgen. Prior to joining Kinetix she was Director of Biology at RiboGene, an antiinfectives company in Hayward, CA and a Project Team Leader in inflammation and cardiovascular therapeutics at Novartis (formerly Ciba-Geigy).

Kevin O’Sullivan, President & CEO, Massachusetts Biomedical Initiatives

Kevin is the President and CEO of Massachusetts Biomedical Initiatives, a private economic development organization that promotes the growth and expansion of the Biotechnology, Medical Device and Bioinformatics industry. MBI operates four life science business incubator facilities in Worcester - located at Gateway Park, Union St and Barber Avenue, home to twenty companies with approximately 100 employees, providing cost effective laboratory space and high quality business development services. He previously served as Vice President and Director of Marketing in a combined public/private partnership position with the Worcester Regional Chamber of Commerce and the City of Worcester where he instituted a comprehensive business and industry development and recruitment plan and was also charged with the opening of the new Convention Center at the DCU Center.

Raj Rajur, PhD, Chairman & CEO, CreaGen Biosciences, Inc.

Dr. Rajur currently serves as Chairman and CEO of a biotechnology company, CreaGen Biosciences, Inc. in Woburn in the Boston area. He holds a PhD degree in synthetic organic/Medicinal chemistry. Rajur's expertise is the broad area of small molecule drug discovery, related to therapeutics in Oncology, Diabetes and anti-infectives and in the development of prodrug pharmaceuticals.           

His academic appointments include stints at the Southwestern Medical Center in Dallas, Center for Engineering in Medicine and Biology at Massachusetts General Hospital and Harvard Medical School, Boston College and Northeastern University. In industry, he successfully led scientific groups at ArQule and Milllipore Corporations. He has published extensively and holds three US patents.

Dr. Rajur, presently also serves as the Program Chair for the Medicinal Chemistry American Chemical Society (NE Chapter) and Co-Chair for the Massachusetts Biotechnology Council CRO/CMO Working Group.



Share MassBio